ExxonMobil Begins Installing Fourth FPSO to Tap Guyana's Reserves
Built by SBM Offshore, the One Guyana FPSO has a production capacity of 250,000 barrels per day. It departed Singapore in mid-February and reached Guyanese waters this week. Once operational, the vessel is expected to help push the consortium's total production capacity to around 940,000 barrels per day by the end of 2025.
The FPSO will support the development of ExxonMobil's Yellowtail and Redtail fields, both located within the giant Stabroek Block. With over 11 billion barrels of recoverable resources discovered, the block has become one of the most significant offshore oil finds in recent history.
After recent upgrades, the company produced an average of 616,000 barrels per day from its three operational FPSOs in 2024. The addition of One Guyana marks a significant step toward boosting that number.
ExxonMobil confirmed the vessel's arrival in a recent statement, noting that production from the Yellowtail project is expected to commence later this year, once installation and well work are complete. According to shipping data, One Guyana is currently positioned near Exxon's three active FPSOs in Guyanese waters.
With two more FPSOs scheduled to arrive over the next two years, ExxonMobil is signaling continued confidence in Guyana's role as a key pillar of its upstream growth strategy. The rapid deployment of infrastructure and consistent production ramp-ups suggest that the South American nation is poised to become a major player in global oil markets, with ExxonMobil at the helm.Top of Form
Bottom of Form
ExxonMobil currently carries a Zack Rank #4 (Sell).
Investors interested in the energy sector may look at some better-ranked stocks like Archrock Inc. AROC, Delek Logistics Partners, LP DKL and Kinder Morgan, Inc. KMI. While Archrock and Delek Logistics Partners presently sport a Zacks Rank #1 (Strong Buy) each, Kinder Morgan carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Archrock is an energy infrastructure company based in the United States with a focus on midstream natural gas compression. AROC provides natural gas contract compression services and generates stable fee-based revenues.
Archrock's earnings beat estimates in three of the trailing four quarters and met once, delivering an average surprise of 8.81%.
Delek Logistics Partners manages and owns systems for moving and storing oil and other products. The company operates pipelines that transport crude oil and refined products like gasoline and diesel. DKL also collects crude oil from different areas and stores it in tanks.
Delek Logistics Partners' earnings beat estimates in two of the trailing four quarters, met once and missed on the other, delivering an average surprise of 79.75%.
Kinder Morgan is a leading North American midstream player with a stable and resilient business model, largely driven by take-or-pay contracts, which ensure consistent earnings and facilitate reliable capital returns to shareholders. KMI operates one of the largest natural gas pipeline networks, positioning it to benefit from the projected increase in U.S. natural gas demand by 2030.
Kinder Morgan's earnings beat estimates in one of the trailing four quarters, met once and missed in the other two, delivering an average negative surprise of 1.85%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Exxon Mobil Corporation (XOM) : Free Stock Analysis Report
Kinder Morgan, Inc. (KMI) : Free Stock Analysis Report
Delek Logistics Partners, L.P. (DKL) : Free Stock Analysis Report
Archrock, Inc. (AROC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
23 minutes ago
- Washington Post
ExxonMobil signs deal to explore for oil and gas near Trinidad despite criticism
PORT-OF-SPAIN, Trinidad — ExxonMobil signed a deal on Tuesday to explore a vast area near Trinidad and Tobago for oil and gas, even as the twin-island nation faces pressure to focus more on green energy deals. The search will take place off Trinidad's east coast, in a region that spans more than 2,700 square miles (7,000 square kilometers) and is more than 6,500 feet (2,000 meters) deep, according to government officials.
Yahoo
35 minutes ago
- Yahoo
Lumentum (LITE) Q4 Earnings and Revenues Top Estimates
Lumentum (LITE) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +7.32%. A quarter ago, it was expected that this optical networking products maker would post earnings of $0.5 per share when it actually produced earnings of $0.57, delivering a surprise of +14%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Lumentum, which belongs to the Zacks Communication - Components industry, posted revenues of $480.7 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.41%. This compares to year-ago revenues of $308.3 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Lumentum shares have added about 37% since the beginning of the year versus the S&P 500's gain of 8.4%. What's Next for Lumentum? While Lumentum has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Lumentum was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.91 on $505.69 million in revenues for the coming quarter and $4.34 on $2.22 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Communication - Components is currently in the bottom 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Ciena (CIEN), has yet to report results for the quarter ended July 2025. The results are expected to be released on September 4. This developer of high-speed networking technology is expected to post quarterly earnings of $0.52 per share in its upcoming report, which represents a year-over-year change of +48.6%. The consensus EPS estimate for the quarter has been revised 0.3% lower over the last 30 days to the current level. Ciena's revenues are expected to be $1.17 billion, up 24.4% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lumentum Holdings Inc. (LITE) : Free Stock Analysis Report Ciena Corporation (CIEN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +29.82%. A quarter ago, it was expected that this company would post a loss of $0.37 per share when it actually produced earnings of $1.9, delivering a surprise of +613.51%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Stoke Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $13.82 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 181.98%. This compares to year-ago revenues of $4.83 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Stoke Therapeutics shares have added about 19.3% since the beginning of the year versus the S&P 500's gain of 8.4%. What's Next for Stoke Therapeutics? While Stoke Therapeutics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Stoke Therapeutics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.62 on $5.02 million in revenues for the coming quarter and $0.13 on $175.67 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 43% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Mersana Therapeutics, Inc. (MRSN), is yet to report results for the quarter ended June 2025. The results are expected to be released on August 13. This company is expected to post quarterly loss of $3.75 per share in its upcoming report, which represents a year-over-year change of +25%. The consensus EPS estimate for the quarter has been revised 0.2% lower over the last 30 days to the current level. Mersana Therapeutics, Inc.'s revenues are expected to be $7.44 million, up 224.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stoke Therapeutics, Inc. (STOK) : Free Stock Analysis Report Mersana Therapeutics, Inc. (MRSN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
